Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Telomerase expression in primary neuroblastomas

C P Reynolds1, J J Zuo, N W Kim

  • 1Department of Pediatrics, University of Southern California School of Medicine, Children's Hospital Los Angeles 90027-0700, USA.

European Journal of Cancer (Oxford, England : 1990)
|March 28, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tabular foundation model predicts alternative lengthening of telomeres (ALT) and identifies SMARCAL1 as a target in ALT-driven cancers.

bioRxiv : the preprint server for biology·2026
Same author

Amino acid transporter SLC6A14 is a novel and effective drug target for pancreatic cancer.

British journal of pharmacology·2016
Same author

The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma.

Blood cancer journal·2014
Same author

Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models.

British journal of cancer·2010
Same author

Human neuroblastoma: Glial induced morphological differentiation.

Neuroscience letters·2009
Same author

Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2005
Same journal

Early-onset colorectal cancer across Europe: Burden, mechanisms, and health-system implications.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Clinical urgency of incidental findings in the first year of the 4-IN-THE-LUNG-RUN lung cancer screening program.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trials.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Left behind but not left alone: Excluded cell populations in the non-small cell lung cancer stroma predict superior long-term overall survival.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Survival outcomes of adjuvant therapy in resected stage III melanoma: Results from a real-life cohort study (TAMARIS).

European journal of cancer (Oxford, England : 1990)·2026
See all related articles

High telomerase RNA component (hTR) levels are found in many neuroblastomas, increasing with disease stage. This suggests that hTR expression may play a role in the progression of this childhood cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Telomeres are crucial for chromosomal stability and cell proliferation.
  • Telomerase is the enzyme responsible for telomere maintenance, primarily active in germline cells.
  • Dysregulation of telomerase activity is observed in many cancers, including neuroblastoma.

Purpose of the Study:

  • To investigate the expression levels of the RNA component of human telomerase (hTR) in primary neuroblastomas.
  • To correlate hTR expression with the clinical stage at diagnosis in neuroblastoma patients.

Main Methods:

  • Northern blot analysis was used to quantify hTR expression.
  • 150 primary untreated neuroblastoma samples were analyzed.
  • hTR expression levels were compared to a cell line control and correlated with disease stage.

Related Experiment Videos

Main Results:

  • Elevated hTR expression (relative to control) was detected in 41% of neuroblastoma tumors.
  • The frequency of high hTR expression increased significantly with higher clinical stages of the disease.
  • A positive correlation was observed between hTR expression levels and disease progression.

Conclusions:

  • hTR expression is frequently elevated in neuroblastomas.
  • Increased hTR expression is associated with advanced disease stages.
  • hTR expression may be implicated in the progression and development of neuroblastoma.